Ovarian Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 trial evaluated the feasibility and safety of personalized neoantigen-targeting cancer vaccines (“NeoVax”) combined with anti-PD-1 in ten patients with high-grade epithelial ovarian cancer. The study found the vaccine feasible, with 9 of 12 evaluable Cohort B patients (75%) vaccinated, and safe, reporting no unexpected toxicities or discontinuations. Biomarker analysis suggested biologic activity in 6 of 10 patients, associated with broader immune responses and immune-selective pressure on tumor clones. These findings support the continued development of personalized neoantigen vaccines as a promising therapeutic strategy for ovarian cancer.
10.1038/s41591-026-04717-8
Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This review examines emerging molecular targets and early-phase drug development strategies for gynecological malignancies, focusing on overcoming treatment resistance through biomarker-driven therapies. The authors highlight novel agents targeting DNA damage response pathways, such as WEE1 and PKMYT1, alongside specific alterations like TP53 Y220C and the rapid expansion of antibody-drug conjugates. For clinicians, these developments represent a significant shift toward precision oncology, offering potential alternatives to conventional chemotherapy for recurrent or treatment-resistant cancers. While tumor heterogeneity and resistance persist, the integration of these targeted therapies into clinical sequencing protocols is essential for improving patient outcomes in oncology practice.
10.1016/j.annonc.2026.10.101
Oct 05 – Oct 12, 2026
Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This phase 1 study evaluated Sofetabart mipitecan (Sofe-M), a novel FRα-targeting antibody-drug conjugate, in 105 heavily pretreated high-grade ovarian cancer (HGOC) patients. Sofe-M achieved an overall response rate of 50.5% (95% CI 40.5, 60.4) and median progression-free survival of 8.1 months (95% CI 6.4, 8.5), showing activity across FRα expression levels and prior MIRV exposure. The drug demonstrated a favorable tolerability profile, notably absent of keratopathy and high-grade neuropathy, addressing a critical need for well-tolerated treatments in advanced HGOC. These data support 3 mg/kg as the recommended phase 3 dose, positioning Sofe-M as a promising new therapeutic option for platinum-resistant and previously treated HGOC patients.
10.1016/j.annonc.2026.10.001
Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 2 trial evaluated neoadjuvant niraparib monotherapy as a chemotherapy-free alternative for 67 patients with HRD-positive, unresectable high-grade serous ovarian cancer. Results demonstrated an investigator-assessed objective response rate of 63% and an R0 resection rate of 80% among the operated population. While effective in enabling surgery, grade 3-4 hematological toxicities were frequent, with thrombocytopenia occurring in 48% of participants. This strategy offers a potential targeted approach for molecularly selected patients, though randomized comparison against standard platinum-taxane chemotherapy is required before clinical adoption.
10.1016/S1470-2045(26)00387-6
Sep 28 – Oct 05, 2026
Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer: A Review.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This review evaluates treatment intensification strategies for patients with poorly chemosensitive, high-grade serous ovarian cancer who often fail to achieve complete cytoreductive surgery. Analysis of phase 3 trials like ICON-8 indicates that weekly dose-dense paclitaxel and bevacizumab provide significant survival benefits specifically within this high-risk “2 red flags” subgroup. The study emphasizes using pragmatic indicators like the KELIM score and pathological chemotherapy response to identify patients for response-adapted first-line therapies. These findings offer a clinically actionable framework to improve interval cytoreduction rates and long-term outcomes in a population with historically limited treatment options.
10.1001/jamaoncol.2026.3875
Sep 07 – Sep 14, 2026
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This phase 3, randomized, double-blind trial evaluated pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance as first-line treatment for advanced BRCA non-mutated epithelial ovarian cancer. The pembrolizumab-olaparib regimen significantly improved progression-free survival (PFS) versus control in the intention-to-treat population (HR 0·68 [95% CI 0·58-0·81]; p<0·0001), with the benefit maintained at final analysis (HR 0·71). Pembrolizumab alone did not show significant PFS improvement, but the combination directly addresses a critical need for improved first-line therapies in this specific cancer subtype. This regimen could represent a clinically meaningful advancement for newly diagnosed stage III-IV BRCA non-mutated epithelial ovarian cancer patients.
10.1016/S1470-2045(26)00223-8
Aug 24 – Aug 31, 2026
Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This article evaluates the applicability of the ESTRO-EORTC oligometastatic disease classification system specifically within the context of ovarian cancer management. The authors identify significant challenges in lesion enumeration and classification due to the diffuse nature of peritoneal spread, which often complicates standard metastatic definitions. Clinically, the study highlights the emerging role of stereotactic radiotherapy for local control in patients with low metastatic burden despite these classification hurdles. It concludes by advocating for a multidisciplinary, disease-specific framework to harmonize clinical trial eligibility and improve prognostic stratification for ovarian cancer patients.
10.1016/S1470-2045(26)00296-2